Confo Therapeutics has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialization of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) for the treatment of neurological and developmental disorders.   Under the terms of the agreement, Roche gains exclusive rights to the compounds resulting from the collaboration and will be responsible for their development, manufacturing and commercializatio...